NCT05153343View on ClinicalTrials.gov

Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 27, 2021

Primary Completion Date

November 29, 2023

Study Completion Date

March 19, 2025

Conditions
Myeloproliferative Neoplasm (MPN)Myelofibrosis，MF
Interventions
DRUG

flonoltinib 25mg

1 case,The starting dose.Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.

DRUG

flonoltinib 100mg

Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.

DRUG

flonoltinib 150mg

Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.

DRUG

flonoltinib 225mg

Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.

DRUG

flonoltinib 50mg

Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.

Trial Locations (1)

610000

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY

NCT05153343 - Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | Biotech Hunter | Biotech Hunter